{"id":54571,"date":"2025-10-15T07:08:30","date_gmt":"2025-10-15T11:08:30","guid":{"rendered":"https:\/\/stockmarketwatch.com\/stock-market-news\/eli-lillys-oral-glp-1-orforglipron-shines-in-phase-3-bank-of-america-delivers-strong-q3-earnings\/54571\/"},"modified":"2025-10-15T07:08:30","modified_gmt":"2025-10-15T11:08:30","slug":"eli-lillys-oral-glp-1-orforglipron-shines-in-phase-3-bank-of-america-delivers-strong-q3-earnings","status":"publish","type":"post","link":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/eli-lillys-oral-glp-1-orforglipron-shines-in-phase-3-bank-of-america-delivers-strong-q3-earnings\/54571\/","title":{"rendered":"Eli Lilly&#8217;s Oral GLP-1 Orforglipron Shines in Phase 3, Bank of America Delivers Strong Q3 Earnings"},"content":{"rendered":"<h2>Key Takeaways<\/h2>\n<ul>\n<li><strong>Eli Lilly&#39;s (<a href=\"\/stock\/LLY\">LLY<\/a>)<\/strong> oral GLP-1 drug, <strong>Orforglipron<\/strong>, demonstrated superior glycemic control in two successful Phase 3 trials, positioning it as a potential foundational treatment for <strong>Type 2 Diabetes<\/strong> with regulatory submission planned for <strong>2026<\/strong>.<\/li>\n<li><strong>Bank of America (<a href=\"\/stock\/BAC\">BAC<\/a>)<\/strong> reported robust <strong>Q3 2025<\/strong> earnings, with <strong>revenue<\/strong> of <strong>$28.09 billion<\/strong> and <strong>Net Interest Income (NII)<\/strong> of <strong>$15.23 billion<\/strong>, both surpassing analyst estimates. The bank also provided an optimistic outlook, forecasting <strong>Q4 NII FTE<\/strong> between <strong>$15.6 billion<\/strong> and <strong>$15.7 billion<\/strong>.<\/li>\n<li><strong>Dollar Tree (<a href=\"\/stock\/DLTR\">DLTR<\/a>)<\/strong> reaffirmed its <strong>Q3 and FY25 outlook<\/strong> after reporting <strong>Q3 2025 same-store sales growth of 3.8%<\/strong> and projecting strong <strong>FY 2026 EPS growth of 12% to 15% CAGR<\/strong>.<\/li>\n<li>Regional banks <strong>PNC Financial (<a href=\"\/stock\/PNC\">PNC<\/a>)<\/strong> and <strong>First Horizon (<a href=\"\/stock\/FHN\">FHN<\/a>)<\/strong> also delivered solid <strong>Q3 2025<\/strong> results, with both reporting adjusted EPS that comfortably beat analyst expectations.<\/li>\n<\/ul>\n<h2>Pharmaceutical Breakthrough: Eli Lilly&#39;s Orforglipron<\/h2>\n<p><strong>Eli Lilly (<a href=\"\/stock\/LLY\">LLY<\/a>)<\/strong> has announced significant progress for its oral GLP-1 receptor agonist, <strong>Orforglipron<\/strong>, in the treatment of <strong>Type 2 Diabetes<\/strong>. The drug demonstrated <em>superior glycemic control<\/em> in two successful Phase 3 trials, reinforcing its potential as a foundational treatment option.<\/p>\n<p>The pharmaceutical giant plans to submit <strong>Orforglipron<\/strong> for regulatory approval in <strong>Type 2 Diabetes<\/strong> in <strong>2026<\/strong>, a move that could significantly expand its presence in the burgeoning diabetes and weight management market. This development highlights the ongoing innovation in oral GLP-1 therapies, offering patients a convenient alternative to injectable treatments.<\/p>\n<h2>Bank of America&#39;s Strong Q3 Performance<\/h2>\n<p><strong>Bank of America (<a href=\"\/stock\/BAC\">BAC<\/a>)<\/strong> reported impressive <strong>Q3 2025<\/strong> earnings, exceeding market expectations across several key metrics. The bank posted <strong>revenue<\/strong> of <strong>$28.09 billion<\/strong>, outperforming estimates of <strong>$27.59 billion<\/strong>. <strong>Net Interest Income (NII)<\/strong> reached <strong>$15.23 billion<\/strong>, also above the estimated <strong>$15.03 billion<\/strong>.<\/p>\n<p>Further bolstering its strong quarter, <strong>Bank of America&#39;s<\/strong> <strong>Q3 EPS<\/strong> came in at <strong>$1.06<\/strong>. The bank also reported <strong>trading revenue excluding DVA<\/strong> of <strong>$5.35 billion<\/strong>, surpassing the <strong>$5.01 billion<\/strong> estimate, and <strong>investment banking revenue<\/strong> of <strong>$2.01 billion<\/strong>, well above the <strong>$1.61 billion<\/strong> estimate. Looking ahead, the bank anticipates <strong>Q4 NII FTE<\/strong> to be between <strong>$15.6 billion<\/strong> and <strong>$15.7 billion<\/strong>, indicating continued positive momentum.<\/p>\n<h2>Dollar Tree Reaffirms Outlook Amidst Q3 Results<\/h2>\n<p>Discount retailer <strong>Dollar Tree (<a href=\"\/stock\/DLTR\">DLTR<\/a>)<\/strong> released its <strong>Q3 2025<\/strong> earnings, reporting <strong>same-store sales growth of 3.8%<\/strong>. While this figure was lower than the previous <strong>6.5%<\/strong>, the company reaffirmed its <strong>Q3 and FY25 outlook<\/strong>.<\/p>\n<p><strong>Dollar Tree<\/strong> also provided an optimistic forecast for the coming fiscal year, projecting <strong>FY 2026 EPS growth of 12% to 15% CAGR<\/strong>. This outlook suggests management&#39;s confidence in future performance despite a slight deceleration in same-store sales growth.<\/p>\n<h2>Regional Banks Report Solid Earnings<\/h2>\n<p>Beyond the major players, regional banks also showcased solid financial performance in <strong>Q3 2025<\/strong>. <strong>PNC Financial (<a href=\"\/stock\/PNC\">PNC<\/a>)<\/strong> reported <strong>adjusted EPS of $4.35<\/strong>, beating the estimated <strong>$4.02<\/strong>, on <strong>revenue of $5.9 billion<\/strong>, exceeding estimates of <strong>$5.82 billion<\/strong>.<\/p>\n<p>Similarly, <strong>First Horizon (<a href=\"\/stock\/FHN\">FHN<\/a>)<\/strong> delivered <strong>adjusted EPS of $0.51<\/strong>, surpassing the <strong>$0.45<\/strong> estimate. The bank&#39;s <strong>loans at end-period<\/strong> stood at <strong>$63.1 billion<\/strong>, slightly below the <strong>$63.82 billion<\/strong> estimate, while <strong>deposits at end-period<\/strong> were <strong>$65.5 billion<\/strong>, compared to an estimated <strong>$66.14 billion<\/strong>. These results indicate resilience within the regional banking sector.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways Eli Lilly&#39;s (LLY) oral GLP-1 drug, Orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, positioning [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":50383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"rank_math_schema_Article":[],"rank_math_focus_keyword":[],"rank_math_description":[],"financial_data_references":[],"stock_symbols_mentioned":[],"footnotes":""},"categories":[5012],"tags":[5453,28,6279,76,6761,205,6801,337,9442,448,10505,1807,10978,3470,12772,4934,5417],"class_list":["post-54571","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","tag-retail","tag-bac","tag-dollar-tree","tag-dltr","tag-eli-lilly","tag-fhn","tag-glp-1","tag-lly","tag-orforglipron","tag-pnc","tag-pnc-financial","tag-earnings","tag-type-2-diabetes","tag-financials","tag-first-horizon","tag-bank-of-america","tag-nii"],"_links":{"self":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/54571","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/comments?post=54571"}],"version-history":[{"count":0,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/54571\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media\/50383"}],"wp:attachment":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media?parent=54571"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/categories?post=54571"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/tags?post=54571"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}